Clinical trial · Observational
Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents
NCT01341132CI-TRIAL-00004723unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to determine whether or not gadoxetate disodium (Eovist) enhanced magnetic resonance imaging (MRI) has a higher sensitivity for detecting hepatocellular carcinoma (Liver Cancer) comparison to multi-detector computed tomography (CT).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI Scan of the Liver enhanced with Eovist | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Suspected Liver Disease
- description
- 1. Alpha-feto protein \> 400 ng / mL or 2. prior ultrasound with mass suspicious for hepatic malignancy or. 3. clinical risk of hepatocellular carcinoma or 4. prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma
- interventionNames
- Procedure: MRI Scan of the Liver enhanced with Eovist
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Alpha-feto protein \> 400 ng / mL or * prior ultrasound with mass suspicious for hepatic malignancy or. * clinical risk of hepatocellular carcinoma or * prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma Exclusion Criteria: * Glomerulo-filtration rate \< 50 mL/ min/1.73 m2 based on a creatinine measurement within three months of the MR study * Previous diagnosis of hepatic malignancy * Any conditions that would discount the ability to have an MRI scan
References
Publications (0)
Data not yet available
No reference posted for this study.